B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: : B7 ligand family members have been shown to be important immunoregulatory factors in host tumor immune responses. We hypothesized that B7-H3, a coinhibitory factor, is expressed by primary breast cancer cells and associated with metastasis to regional tumor-draining lymph nodes. EXPERIMENTAL DESIGN: : American Joint Committee on Cancer stage I to III primary breast cancers (n = 82) and normal breast specimens (n = 17) were assessed for B7-H3 expression using paraffin-embedded archival tissues. B7-H3 expression by breast cancer cells was assessed by a quantitative real-time reverse transcription-polymerase chain reaction, and B7-H3 protein expression was evaluated using immunohistochemistry. RESULTS: : B7-H3 mRNA expression was detected in 32 of 82 (39%) primary breast tumors but not in normal breast tissues (P = 0.0029). B7-H3 expression in primary tumors significantly correlated with increasing tumor size, American Joint Committee on Cancer stage, and lymphovascular invasion (P < 0.0001, P < 0.0001, P = 0.0071). B7-H3 expression was highly correlated to sentinel lymph node and overall number of lymph nodes with metastasis P = 0.003, and P = 0.004, respectively). In a multivariate analysis, B7-H3 mRNA expression of the primary tumor significantly predicted metastasis to regional lymph nodes (P = 0.021, and P = 0.023, respectively). Antibody staining analysis of paraffin-embedded archival tissue breast tumors and flow cytometry of breast cancer cell lines demonstrated B7-H3 protein expression. CONCLUSIONS: : B7-H3 protein expressed by primary breast cancer cells is a tumor progression factor and is associated with extent of regional nodal metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“0001 >2 cm and ≤5 cm (T2) 14 (28) 8 (25) >5 cm (T3) 9 (18) 23 (72) AJCC stage I 18 (36) 1 (3) <0.”
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 1×
“Negative 22 (82) 10 (59) 7 (33) 40 (61) 0.”
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · cited 4×
“Negative 24 (83) 15 (60) 11 (39) 50 (61) 0.”
Influential
Cited by
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
Seaman, S., Zhu, Z., Saha, S., Zhang, X. M., Yang, M. Y., Hilton, M. B., Morris, K., Szot, C., Morris, H., Swing, D. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.005 · Cited by 423
B7 family checkpoint regulators in immune regulation and disease
Ceeraz, S., Nowak, E. C., & Noelle, R. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.003 · Cited by 307
B7-H3/CD276: An Emerging Cancer Immunotherapy
Zhou, W.-T., & Jin, W.-L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701006 · Cited by 295
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
Metadata
- Authors
- Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A., Giuliano, A. E., & Hoon, D. S. B.
- Venue
- Annals of Surgery
- Published
- 2010-12
- Volume
- 252
- Issue
- 6
- Pages
- 1044-1051
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2026989399
- Cited by
- 146
- References
- 13
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis. https://app.cochat.ai/papers/10.1097/sla.0b013e3181f1939d
- The paper
- Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A., Giuliano, A. E., & Hoon, D. S. B. (2010). B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis. Annals of Surgery. https://doi.org/10.1097/sla.0b013e3181f1939d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.